Table 2 Sustained Virologic Responses (SVR), Odds Ratios (OR) and 95% Confidence Intervals (CI) analyses for all patients, genotype 1, 3 and regimen-specific subgroups

Treatment regimens

Pegylated IFN-α2a and RBV 1000 mg

Pegylated IFN-α2a and RBV 1200 mg

Pegylated IFN-α2b and RBV 1000 mg

Pegylated IFN-α2b and RBV 1200 mg

Control

16

TD

4

Control

12

TD

3

Control

8

TD

2

Control

8

TD

2

EVR*

Not applicable (see text)

ETR - number (%)

9

(56.3%)

3

(75.0%)

9

(75.0%)

3

(100.0%)

4

(50.0%)

2

(100.0%)

5

(62.5%)

2

(100.0%)

SVR - number (%)

8

(50.0%)

3

(75.0%)

7

(58.3%)

2

(66.6%)

4

(50.0%)

2

(100.0%)

5

(62.5%)

2

(100.0%)

GENOTYPE 3 (N = 40)

Treatment regimens

Pegylated IFN-α2a and RBV 800 mg

Pegylated IFN-α2b and RBV 800 mg

Control

N = 16

TD

N = 4

Control

N = 16

TD

N = 4

EVR*

Not applicable (see text)

ETR - number (%)

16

(100.0%)

4

(100.0%)

16

(100.0%)

4

(100.0%)

SVR - number (%)

16

(100.0%)

4

(100.0%)

16

(100.0%)

4

(100.0%)

SVR for genotype 1: Odds Ratio, 95% CI

5.2, 1.2 to 22.3

SVR for genotype 3

Control (n = 32) 100.0%

TD (n = 8 ) 100.0%

All 40 cases achieved SVR making the combination of Genotype 3 and TD a perfect predictor of SVR in this group.

Treatment related SVR IFN-α2a vs IFNα2b

Non Statistically Significant

OVERALL SVR: ODDS RATIO, 95% CI

6.0, 1.5 to 24.6